Core Viewpoint - The research paradigm of AI for Science (AI4S) is revolutionizing scientific research by breaking the limitations of traditional "experimental discovery" and "manual equation derivation" through advanced modeling, simulation, and prediction in quantum, atomic, and continuous medium systems [1] Group 1: AI in Pharmaceuticals - The industry outlook for AI in pharmaceuticals is positive, with expectations for commercialization by 2026 driven by deepening collaborations in small molecule drugs and explosive growth in large molecule antibody fields [1] - The large molecule sector, particularly antibodies, is anticipated to be the biggest growth highlight by 2026, as AI can efficiently explore vast protein sequence spaces to design new antibodies with better characteristics [1] Group 2: AI in Material Science - AI new materials are expected to become a key application and investment direction within AI4S, as AI accelerates material discovery and optimizes digital processes, serving as a core engine for upgrading the manufacturing industry [1] Group 3: Investment Products - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects listed companies in the fields of innovative drug research and biopharmaceuticals from the Chinese A-share market to reflect the overall performance of innovative pharmaceutical-related listed companies [1]

Group 1 - The core viewpoint of the article highlights the recovery of the innovative drug sector, with continuous capital inflow and a positive cycle driven by favorable policies, accelerated R&D, and international expansion [1] - The innovative drug ETF Guotai (517110) saw an intraday increase of over 2.4%, with a net capital inflow exceeding 200 million yuan in the past 20 days [1] - Multiple brokerages indicate that the domestic innovative drug industry is entering a favorable cycle characterized by normalized medical insurance negotiations, continuous clinical data releases, and successful License-out orders, enhanced by AI-driven R&D acceleration [1] Group 2 - The industry valuation is currently at a historical low to mid-range, with institutional allocation being relatively low, indicating ample room for future increases [1] - The innovative drug ETF Guotai (517110) tracks the CSI Hong Kong-Shenzhen-Shanghai Innovative Drug Industry Index (931409), which selects high-quality companies with strong R&D capabilities focused on biopharmaceuticals and chemical drug innovation [1] - The index includes leading innovative drug companies and high-growth targets, accurately reflecting the performance of the core medical innovation sector, with long-term growth potential and investment value [1]

Core Viewpoint - The recent decline of nearly 3% in the Cathay Innovation Drug ETF (517110) presents a potential opportunity for investment in Chinese raw material pharmaceutical companies, which are expected to strengthen their competitive advantages [1]. Industry Summary - China's pharmaceutical and healthcare product export value is projected to grow by 3.14% by 2025, with a slight decrease of 0.27% in the export value of Western medicine raw materials [1]. - The stability in raw material drug exports reflects the competitiveness of China's raw material pharmaceutical industry amidst global trade changes and internal price competition [1]. - The outlook for 2026 indicates continued uncertainty in raw material trade, driven by price competition and advancements in synthetic biology and new production technologies that lower unit costs [1]. - Upgrades in technology are enhancing the global competitiveness of Chinese raw material pharmaceutical companies [1]. - A trend of supply clearing is ongoing, with some product prices continuing to decline; however, the potential for significant further price drops is limited compared to historical averages [1]. - Price competition pressures are beginning to impact the profits of leading companies [1]. - The competitive advantages of Chinese raw material pharmaceutical companies are expected to strengthen by 2026, with some product prices having likely bottomed out, leading to potential price recovery due to changes in competitive dynamics and production capacity utilization [1]. Company Summary - The Cathay Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which focuses on publicly listed companies engaged in the research, production, and sales of innovative drugs in the Shanghai, Shenzhen, and Hong Kong markets [1].

Core Viewpoint - The innovation-driven pharmaceutical sector in China is experiencing significant growth, with a shift from traditional growth drivers to innovative ones, supported by demographic changes and advancements in technology [1]. Group 1: Industry Transformation - The Chinese pharmaceutical industry has completed a transformation from old to new growth drivers between 2015 and 2025, with innovation opening new growth trajectories for companies [1]. - Traditional pharmaceutical companies have successfully transitioned to innovation-focused models, enhancing their global competitiveness [1]. Group 2: Market Dynamics - The demand side is bolstered by an aging population and an increase in chronic disease prevalence, while the payment side benefits from stable growth in medical insurance revenues and the establishment of a multi-tiered payment system [1]. - The rapid development of new technologies, such as AI, brain-computer interfaces, and cancer early screening, is expected to drive further industry transformation and growth [1]. Group 3: Investment Opportunities - The Cathay Innovation Drug ETF (517110) has seen over 1.4% increase in intraday trading and has experienced net inflows for five consecutive days, indicating strong investor interest in innovation-focused pharmaceutical technology [1]. - The ETF tracks the SHS Innovation Drug Index (931409), which selects listed companies with strong R&D capabilities and growth potential in the biopharmaceutical and chemical pharmaceutical sectors [1].

Market Overview - A-shares opened high but closed lower, with the Shanghai Composite Index down 0.64%, Shenzhen Component Index down 1.37%, and ChiNext Index down 1.96%. The total trading volume in the Shanghai and Shenzhen markets was approximately 3.70 trillion yuan, showing a slight increase compared to the previous trading day. More than 3,700 stocks declined [1] Industry Insights - The commercial aerospace sector saw significant activity, leading to a market pullback. However, this correction is considered normal after continuous gains, and the spring market trend is expected to continue. Investors are advised to focus on technology growth and related sectors such as commercial aerospace, AI applications, and new energy, while also considering cash flow/dividend assets to mitigate market volatility [1] - The medical services, precious metals, and GEO concept stocks were among the top gainers today, while commercial aerospace, semiconductors, and chemical fiber industries experienced the largest declines [1] Pharmaceutical Sector Highlights - The pharmaceutical sector led the market gains due to several key developments: 1. Rongchang Bio signed an exclusive licensing agreement with AbbVie for RC148, with a total transaction value of 5.6 billion USD, highlighting the significant market potential of the PD-1/VEGF dual antibody track [2] 2. WuXi AppTec, a leading CXO, announced its 2025 performance forecast, expecting annual revenue of 45.456 billion yuan, a year-on-year increase of 15.84%, exceeding expectations [2] 3. Tempus AI reported better-than-expected earnings, with diagnostic business revenue of 955 million USD, a year-on-year growth of 111%, indicating ongoing global advancements in AI medical technology [2] - The pharmaceutical sector's global competitiveness continues to strengthen, with ongoing international expansion and commercial profitability [2] Power Grid Sector Developments - The domestic power grid performed relatively well in the afternoon, driven by the demand for renewable energy consumption from large-scale wind and solar projects. The vast territory of China necessitates long-distance transportation, which is expected to further stimulate demand for UHV (Ultra High Voltage) construction. During the 14th Five-Year Plan period, UHV DC is expected to maintain an annual approval pace of 3 to 4 lines, while UHV AC is anticipated to approve an average of 2 large projects annually [2] - In North America, explosive growth in AIDC (Artificial Intelligence Data Center) is creating new electricity demand, and China's complete power grid industry chain, efficient delivery, and rich overseas experience position it as a key supplier to fill this gap [2]

========= - The CSI 500 Index performed well among scale indices, with the CSI 500 Growth Index rising by 2.37%[6] - The ChiNext Index performed well among sector indices, with the ChiNext Index rising by 3.39%[6] - The Communication, Nonferrous Metals, Electronics, Basic Chemicals, and Non-Banking sectors performed well, with returns of 4.92%, 3.15%, 2.58%, 2.36%, and 2.01% respectively[7] - The Agricultural, Forestry, Animal Husbandry, and Fishery, National Defense and Military, Coal, Comprehensive, and Real Estate sectors performed poorly, with returns of -0.41%, -0.25%, -0.18%, -0.16%, and 0.02% respectively[7] - The concepts of Optical Module (CPO), Lithium Mine, Lithium Battery Electrolyte, Lithium Hexafluorophosphate, and Optical Communication performed well, with returns of 6.59%, 6.39%, 5.36%, 5.28%, and 5.03% respectively[10] - The concepts of Hainan Free Trade Port, Horse Racing, Cross-Strait Integration, Satellite Internet, and Commercial Space performed poorly, with returns of -3.27%, -2.81%, -2.15%, -2.15%, and -1.86% respectively[10] - The highest number of stocks hitting the daily limit during the day was 59, with 58 stocks hitting the limit at the close[13] - The highest number of stocks hitting the daily limit during the day was 28, with 27 stocks hitting the limit at the close[13] - The closing return of stocks that hit the daily limit yesterday was 0.14%, while the closing return of stocks that hit the daily limit yesterday was -2.37%[14] - The sealing rate today was 72%, an increase of 7% from the previous day, and the continuous sealing rate was 22%, a decrease of 1% from the previous day[17] - The balance of margin financing and securities lending as of December 16, 2025, was 2,504.8 billion yuan, with a financing balance of 2,488.1 billion yuan and a securities lending balance of 16.7 billion yuan[19] - The balance of margin financing and securities lending accounted for 2.7% of the market's circulating market value, and the margin financing and securities lending transactions accounted for 10.2% of the market's transaction value[22] - The large-cap growth ETF had the highest premium on December 16, 2025, with a premium of 1.15%, while the innovative drug ETF Guotai had the highest discount, with a discount of 0.70%[23] - The average daily transaction amount of block trades in the past six months reached 2.1 billion yuan, and the transaction amount on December 16, 2025, was 1.6 billion yuan[26] - The average discount rate of block trades in the past six months was 6.63%, and the discount rate on December 16, 2025, was 4.62%[26] - The annualized discount rate of the main contracts of the SSE 50, CSI 300, CSI 500, and CSI 1000 stock index futures in the past year were 0.89%, 3.73%, 11.22%, and 13.67% respectively[28] - The annualized discount rate of the main contract of the SSE 50 stock index futures on December 17, 2025, was 18.71%, at the 2% percentile in the past year[28] - The annualized discount rate of the main contract of the CSI 300 stock index futures on December 17, 2025, was 4.57%, at the 41% percentile in the past year[28] - The annualized premium rate of the main contract of the CSI 500 stock index futures on December 17, 2025, was 15.70%, at the 100% percentile in the past year[28] - The annualized premium rate of the main contract of the CSI 1000 stock index futures on December 17, 2025, was 10.74%, at the 100% percentile in the past year[28] - The stocks with the most institutional research in the past week were Changan Automobile, Yipin Red, Boke Shares, Fuchuang Precision, Boying Special Welding, Zhishang Technology, Ruide Intelligent, and Kaizhong Shares, with Changan Automobile being researched by 214 institutions[30] - The top ten stocks with net inflows from institutional special seats on December 17, 2025, were Juguang Technology, Shenzhen Southern Circuit, Hualing Cable, Shengxin Lithium Energy, Shunhao Shares, Kaipu Cloud, Western Materials, Tongyu Communications, Liante Technology, and Gu'ao Technology[36] - The top ten stocks with net outflows from institutional special seats on December 17, 2025, were Yingwei Ke, Snowman Group, Guangxun Technology, Zhongchao Holdings, Biological Shares, Tianji Shares, Sun Cable, Sanyang Horse, Eurasia Group, and Qujiang Cultural Tourism[36] - The top ten stocks with net inflows from Northbound Trading on December 17, 2025, were Shenzhen Southern Circuit, Shengxin Lithium Energy, Aerospace Electromechanical, Guangxun Technology, Hualing Cable, Chaoxun Communications, Chinese Health, and Tongyu Communications[37] - The top ten stocks with net outflows from Northbound Trading on December 17, 2025, were Snowman Group, Biological Shares, Juguang Technology, Yidong Electronics, Aerospace Changfeng, Yingwei Ke, Liante Technology, and Western Materials[37] =========

Group 1 - The pharmaceutical and biotechnology industry in China is expected to show multiple positive signals by 2025, with the market size projected to exceed 400 billion yuan in 2024, and 113 domestic innovative drugs approved during the "14th Five-Year Plan" period, which is 2.8 times that of the "13th Five-Year Plan" period [1] - The total amount of License-out projects for innovative drugs has reached a new record, with preclinical projects accounting for 68%, indicating that Chinese innovative drugs are gradually gaining global recognition [1] - The chemical pharmaceutical sector is leading the market driven by innovative drugs and AI healthcare, with the pharmaceutical sector's valuation approaching the historical average over the past 10 years, and public fund holdings showing a quarterly increasing trend [1] Group 2 - In the medical device sector, the bidding market size in Q3 2025 is expected to grow by 29.8% year-on-year, with revenue turning points emerging for medical device companies, driven by continuous demand release from equipment renewal policies [1] - The brain-computer interface field is accelerating development under policy support, with national and local governments expected to introduce supportive policies in 2025, and global companies like Neuralink driving technological iteration and clinical applications [1] - The industry is facing a transformation in the payment system, with significant growth potential for commercial health insurance, which is expected to promote the transition of innovative drug payments from a "single" to a diversified payment model [1] Group 3 - The Guotai Innovative Drug ETF (517110) tracks the SHS Innovative Drug Index (931409), which selects listed companies involved in the research and development of chemical and biological drugs from the Shanghai, Hong Kong, and Shenzhen markets to reflect the overall performance of the innovative drug sector [2] - The index consists of 50 constituent stocks, indicating a high industry concentration, focusing on innovative drug companies with growth potential and research-driven characteristics [2]

Group 1 - The core viewpoint is that the innovative pharmaceutical sector is experiencing sustainable growth due to the continuous implementation of BD, with a trend towards "innovation + internationalization" remaining unchanged [1] - After a short-term adjustment, the elasticity of the innovative pharmaceutical sector has further increased, indicating a positive outlook [1] - There is a noticeable improvement in the fundamentals of the innovative pharmaceutical industry chain, with positive trends observed in investment and financing data, orders, and performance [1] Group 2 - The Guotai Innovative Drug ETF (517110) tracks the SHS Innovative Drug Index (931409), which focuses on listed companies in the A-share and Hong Kong markets engaged in innovative drug research and biopharmaceuticals [1] - The index selects 50 high-growth and volatile constituent stocks, reflecting the overall performance of innovative pharmaceutical enterprises, with a growth-oriented style primarily allocated in the healthcare sector [1]

Market Overview - The A-share market experienced a decline across major indices last week, with the Shanghai Composite Index, CSI 1000, and CSI 300 showing returns of -0.18%, -0.52%, and -1.08% respectively. In contrast, the STAR 50, ChiNext Index, and SME Board Index had poorer performances with returns of -3.85%, -3.01%, and -1.71% respectively [1] - In terms of industry performance, consumer services, textiles and apparel, and pharmaceuticals led with returns of 4.81%, 4.43%, and 3.29% respectively, while communication, electronics, and computers lagged with returns of -4.90%, -4.44%, and -3.72% respectively [1] Fund Flow - The ETF market saw a net inflow of 29.317 billion yuan last week, with stock ETFs contributing 17.352 billion yuan, QDII stock ETFs 5 billion yuan, commodity ETFs 5.957 billion yuan, money market fund ETFs 1.236 billion yuan, and bond ETFs experiencing a net outflow of 0.276 billion yuan [2] - Specific indices that saw significant net inflows include SGE Gold 9999 (5.573 billion yuan), STAR 50 (3.532 billion yuan), and ChiNext AI (2.300 billion yuan) [4] - Conversely, indices such as CSI A500 and CSI 300 experienced notable net outflows of 4.055 billion yuan and 2.640 billion yuan respectively [2][4] ETF Performance - The median weekly return for stock ETFs was -1.09%, with the CSI 50 ETF showing the highest median return of 0.02% among broad-based ETFs. Consumer ETFs had a median return of 2.10%, the highest among sectors [11] - Top-performing ETFs included the Hong Kong Stock Connect Innovative Drug ETF (10.92%), Hang Seng Innovative Drug ETF (10.80%), and Tourism ETF (9.30%) [12][14] - In contrast, ETFs such as 5G Communication ETF and Communication ETF saw declines of -7.03% and -6.89% respectively [16][18] New Fund Activity - A total of 56 funds were reported last week, an increase from the previous week, including one QDII and several thematic ETFs [20] - 25 new funds were established with a total issuance scale of 14.173 billion yuan, which is a decrease compared to the previous week [20] - 41 funds entered the issuance phase last week, with 33 more expected to begin issuance this week [21] Hot News - Several cross-border ETFs have been flagged for premium risks due to significant discrepancies between market trading prices and net asset values [22] - The "Southbound ETF" program expanded on November 10, adding six ETFs to the Hong Kong Stock Connect list, increasing the total number of products from 17 to 23 [23]

Group 1 - The 2025 National Medical Insurance negotiation has officially introduced the "Commercial Insurance Innovative Drug Directory" mechanism, which aims to include innovative drugs that are not yet part of the basic medical insurance directory but have high clinical value and significant patient benefits [2] - A total of 535 drug generic names have passed the formal review for the basic drug directory, while 121 drug generic names have passed for the commercial insurance innovative drug directory, with 79 of them applying for both directories [2] - The introduction of the commercial insurance innovative drug directory is expected to open up broader market opportunities for innovative drugs in the context of a growing number of "global new" drugs emerging in China [2] Group 2 - The innovative drug industry is currently benefiting from three core positive factors: performance realization, policy support, and improved market environment [3][4] - The performance realization is driven by high-demand business development (BD) transactions, as domestic innovative drug companies have accumulated a wealth of quality patents since 2016, which can effectively complement the needs of large pharmaceutical companies facing patent expirations [3] - Continuous policy support includes the inclusion of 37 high-priced innovative drugs in commercial insurance to supplement the Class C directory of medical insurance, and the optimization of priority review and approval processes, which shortens clinical review to 30 working days [3] Group 3 - The market environment has improved since mid-June 2025, with the A-share market entering a "slow bull" phase, enhancing overall risk appetite and providing strong support for the innovative drug sector [4] - The innovative drug industry is expected to see significant growth opportunities driven by continuous breakthroughs in international markets, ongoing policy benefits, and the steady improvement of R&D capabilities among Chinese innovative drug companies [5] - The Science and Technology Innovation Drug ETF (589720) has outperformed the Hang Seng Hong Kong Stock Connect Innovative Drug Index since the "924 market" began, indicating strong investment potential in this sector [6]